바이오인프라

199730KOSDAQ자연과학 및 공학 연구개발업

49.0 / 100

Reference Date: 2026-06-10

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 23.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioInfral is a CRO established in 2007, specializing in bioequivalence testing for generic drugs, Phase I clinical trials for improved drugs, approval clinical trials, immunoassays, and pharmaceutical quality inspections. The company operates multiple business units, including PK, Clinical, Immunoassay, and Testing, offering diverse services such as drug interaction studies, clinical trial management, biomarker analysis, and stability testing.

Number of Employees

141people

Average Salary

47.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

0.87Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-41.45Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

4.88Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼257.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,935Won52-week high 5,87052-week low 2,935

1-month return0.0Point

1m -23.37% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral분기보고서 (2026.03)2026-05-15